Score breakdown
Strengths & weaknesses
- Owner sentenced to 70 months in federal prison, 30 July 2026
- Forged laboratory certificates, admitted in the guilty plea
- Six government-tested SARMs products all contained testosterone
- Advertised as US-manufactured while importing from China and India
- Falsely claimed FDA registration and in-house testing
- Continued selling after FDA warning letters in 2020 and 2022
- Customers reported cardiac, endocrine and psychiatric harm
Shipping & payment
MEDIAN ACROSS TEST ORDERSAudit notes
FROM THE BENCHWhat happened to Paradigm Peptides?
Paradigm Peptides sold research peptides, SARMs, HCG and other drugs online from 2019 until it shut down in March 2024. On 30 July 2026 the US Attorney's Office for the Northern District of Indiana announced that owner Matthew J. Kawa, 48, of Grant Park, Illinois, had been sentenced to 70 months in federal prison followed by one year of supervised release. His sister and main employee, Jennifer L. Stechkober, 32, of Michigan City, Indiana, received 16 months.
Both pleaded guilty to introducing unapproved new drugs into interstate commerce with the intent to defraud and mislead. Kawa additionally pleaded guilty to illegally importing merchandise. The court entered a $5 million money judgment against Kawa and ordered $78,317.52 in restitution to identified victims.
| Fact | Figure |
|---|---|
| Operating period | 2019 to 2024 |
| Customers | 54,000+ |
| Reach | all 50 states, 80+ countries |
| Proceeds | $5 million |
| FDA warning letters ignored | 2020, 2022 |
| Kawa sentence | 70 months + 1 year supervised release |
| Stechkober sentence | 16 months + 1 year supervised release |
| Restitution | $78,317.52 |
Sentencing judge Cristal C. Brisco told Kawa he had "focused on what you wanted to build instead of thinking about the people," and said he had ignored numerous regulator warnings and left "an incredible trail of harm."
What did Paradigm Peptides claim, and what was true?
This is the part of the case that matters beyond Paradigm, because the claims were not unusual. They are the standard trust signals across this market.
| What the site claimed | What the government established |
|---|---|
| Licensed and registered with the FDA | False |
| Manufactured in its own US laboratories | Imported from China, India and elsewhere |
| Products tested to ensure quality | Not tested before sale |
| 99% purity, third-party tested | Laboratory certificates were forged |
| Safe and of pharmaceutical quality | Six SARMs tested as testosterone |
| For research use only | Kawa admitted knowing products were sold for human consumption |
Every line in the left column is available on working vendor sites today. That is the reason this case belongs on this site rather than in a news roundup, and we have written up the verification angle separately in forged COAs and a 70-month sentence.
What was actually in the vials?
Government laboratories tested six compounds sold as SARMs. All six contained testosterone, a Schedule III controlled substance, rather than the labelled compound. Customers taking what they believed was a non-hormonal research chemical were taking an anabolic steroid without knowing it.
The documented consequences in the court record include chronic acne and skin irritation, suppression of natural testosterone production requiring replacement therapy, cardiac problems, and psychological effects up to suicidal ideation. One customer, who began using Paradigm products in 2023, was later diagnosed with steroid-induced psychosis after independent testing of a retained bottle showed testosterone. He has sued, and Kawa is contesting that suit.
Was there warning before the shutdown?
Yes, and it was public. The FDA sent Kawa warning letters in 2020 and 2022 stating that he was marketing and selling unapproved drugs in violation of the Food, Drug and Cosmetic Act. He continued selling for another two years.
Warning letters are published in the FDA Warning Letters database. A buyer checking that database against a vendor name in 2022 would have found this one. That check takes about a minute and it remains the single cheapest piece of vendor diligence available.
Is the site still operating?
Sites have appeared using packaging and branding that resemble the former Paradigm brand. One such operation has publicly denied any affiliation with Kawa or the original business, and said it would redesign elements that caused concern.
We take no position on who runs those sites. The relevant point for a buyer is narrower: brand continuity is not operator continuity. A recognisable name on a peptide site tells you nothing about who is behind it, where the material comes from, or whether anything has been tested. Nothing on this page should be read as a review of any currently-operating site using this name, and we have not audited one.
Postscript, 6 August 2026 - what we got wrong
An earlier version of this profile recorded Paradigm as having "ceased operations December 2025 following a federal plea," and described the peptide catalog as not being the formal target of the action. Both framings were wrong.
Operations ceased in March 2024, roughly twenty months earlier than we recorded, with the guilty pleas following in 2025 and sentencing in July 2026. And while the SARMs products carried the testosterone finding, the charge both defendants pleaded to was introducing unapproved new drugs into interstate commerce with intent to defraud, which is a description of the business as a whole rather than of one product line. The forged-certificate admission covers the peptide catalog too.
That earlier version also carried customer-migration claims and investigation timeline details we could not source to a primary document. Those have been removed rather than rewritten. This entry is logged in our corrections record.
Lessons this case actually supports
A published purity figure is a marketing claim until it resolves. Paradigm advertised 99% purity and third-party testing while forging the certificates. The number on the product page is not evidence. The certificate that resolves on the issuing lab's own server is. Run one through our COA verifier.
Regulator databases are the cheapest signal available. Two FDA warning letters sat in a public database for years while the business kept selling.
"Research use only" is a label, not a legal shield. Kawa admitted he knew the products were being sold for human consumption. The disclaimer did not protect the company and it does not describe what a vendor believes about its buyers.
Related
- Forged COAs and a 70-month sentence - the verification method this case argues for
- Three vendors closed in 12 months - Paradigm alongside Amino Asylum and Peptide Sciences
- FDA peptide enforcement, 2024-2026 - where this sentencing sits in the enforcement timeline
- How peptide vendors fail: a taxonomy - the failure modes, including fabricated testing
- How to verify a Janoshik COA - the step-by-step check
Sources
5 REFERENCES- Illinois Man and Indiana Woman Sentenced Respectively to 70 Months and 16 Months in Prison for Selling Unapproved Drugs in Interstate Commerce — US Attorney's Office, Northern District of Indiana (30 July 2026)
- United States v. Matthew Kawa - case page — US Department of Justice
- Judge sentences peptide vendor to nearly 6 years in prison for an incredible trail of harm — CBS News (30 July 2026)
- FDA Warning Letters database — FDA
- Forged COAs and a 70-month sentence — vialaudit